ArticleEJHaem2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
Joan How et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleEJHaem2022
Joan How et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.